Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06666712 · ClinicalTrials.gov registry record · Phase 1
Chronic CED of TPT for Recurrent Malignant Glioma
A Phase 1 study of Brain Tumor, Recurrent and Malignant Glioma (WHO Grade III or IV), sponsored by Jeffrey N. Bruce.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06666712 is a Phase 1 study of Brain Tumor, Recurrent and Malignant Glioma (WHO Grade III or IV) that is actively recruiting participants, run by Jeffrey N. Bruce. The registered enrollment target is 6 participants, below the 112-participant average among 6 other Brain Tumor, Recurrent trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06666712, a Phase 1 study of Brain Tumor, Recurrent and Malignant Glioma (WHO Grade III or IV), is actively recruiting participants, sponsored by Jeffrey N. Bruce.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of the chemotherapeutic drug Topotecan for patients with recurrent malignant glioma that harbors the Isocitrate Dehydrogenase mutation (IDH-mut). The secondary goal of the study is to study drug distribution and assess the tumor response to prolonged continuous CED of Topotecan. Convection Enhanced Delivery is a novel method of drug delivery that allows administration of a drug directly to the brain. In CED, a drug pump is placed under the skin in the chest or abdominal region. The pump is connected to a catheter that is tunneled underneath the skin to the brain. The tip of the catheter then infuses Topotecan directly onto the brain tumor. There will be a total of four treatment infusions over the course of 23-29 days, with a 5-7-day rest period between each infusion. Throughout this period, patients' health will be monitored through imaging, blood draws, and regular exams. At the end of the treatment period, the pump will be removed, followed by resection of the tumor. Patients will be followed for the duration of their lives. This is the investigator's second clinical trial studying CED of TPT in recurrent glioma. In the prior Phase 1b trial, chronic pulsatile CED safely and effectively delivered Topotecan to patients with IDH mutant recurrent Glioblastoma (WHO grade 4).
Conditions Studied
Interventions
- DRUG Topotecan
Study Locations (1)
New York
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2026-03 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06666712
The ClinicalTrials.gov registry entry for NCT06666712 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 112-participant average among 6 other Brain Tumor, Recurrent trials with a reported enrollment target (95% lower). The listed sponsor is Jeffrey N. Bruce, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Brain Tumor, Recurrent appearing as the primary indexed condition, and to 1 intervention - of which Topotecan is the first listed.
NCT06666712 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06666712 about?
NCT06666712 is a clinical study titled "Chronic CED of TPT for Recurrent Malignant Glioma". The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of the chemotherapeutic drug Topotecan for patients with recurrent malignant glioma that harbors the Isocitrate Dehydrogenase mutation (IDH-mut). The secondary goal of the study is to study drug d...
What is the current status of trial NCT06666712?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2026-03. Estimated completion is 2028-06.
What conditions does trial NCT06666712 study?
This clinical trial studies the following conditions: Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV), IDH1/IDH2 Mutation.
What interventions are being tested in trial NCT06666712?
The interventions under investigation include: Topotecan (DRUG).
Who is sponsoring clinical trial NCT06666712?
This trial is sponsored by Jeffrey N. Bruce, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06666712 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor, Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
COMPLETED · Phase 1
-
Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors
COMPLETED · Phase 1
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
RECRUITING
-
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Brain Tumor, Recurrent
All registered trials for this condition
Malignant Glioma (WHO Grade III or IV)
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.